Synaptogenix (SNPX) News Today → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free SNPX Stock Alerts $4.91 +0.20 (+4.25%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 7, 2024 | prnewswire.comSynaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug DiscoveryApril 24, 2024 | finanznachrichten.deSynaptogenix, Inc.: Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingApril 24, 2024 | prnewswire.comSynaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingApril 5, 2024 | uk.investing.comSynaptogenix announces reverse stock split to regain Nasdaq complianceApril 5, 2024 | marketbeat.comTrading was temporarily halted for "SNPX" at 07:04 PM with a stated reason of "News pending."April 4, 2024 | msn.comWhat's Going On With Synaptogenix (SNPX) Stock?April 3, 2024 | finance.yahoo.comSynaptogenix Announces Reverse Stock Split to Maintain Nasdaq ListingFebruary 22, 2024 | msn.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 1.18%December 19, 2023 | finance.yahoo.comSynaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative DisordersDecember 6, 2023 | finance.yahoo.comSynaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sNovember 2, 2023 | finance.yahoo.comSynaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of TechnologySeptember 26, 2023 | finance.yahoo.comSynaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's DiseaseSeptember 7, 2023 | finance.yahoo.comBryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent StudyJuly 19, 2023 | prnewswire.comSynaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple SclerosisJuly 14, 2023 | benzinga.comShort Volatility Alert: Synaptogenix IncJuly 13, 2023 | benzinga.comSynaptogenix Shares Halted On Circuit Breaker To The Upside, Stock Now Up 59.1%July 13, 2023 | marketwatch.comSynaptogenix Shares Rise 48% After Alzheimer's Drug Abstract Accepted at ConferenceJuly 13, 2023 | finance.yahoo.comSynaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of NeuroscienceJuly 13, 2023 | marketbeat.comTrading was temporarily halted for "SNPX" at 10:07 AM with a stated reason of "LULD pause."June 24, 2023 | finance.yahoo.comSNPX - Synaptogenix, Inc.March 7, 2023 | finance.yahoo.comSynaptogenix Provides Corporate Update and Outlines Potential Business OpportunitiesFebruary 27, 2023 | reuters.comSNPX.ODecember 20, 2022 | msn.comPeering Into Synaptogenix's Recent Short InterestDecember 16, 2022 | seekingalpha.comSynaptogenix crashes 69% as Phase 2 trial for Alzheimer’s candidate failsDecember 16, 2022 | finance.yahoo.comSynaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's DiseaseDecember 9, 2022 | seekingalpha.comSynaptogenix: Bryostatin For Alzheimer's, As Binary As Can BeNovember 18, 2022 | seekingalpha.comSynaptogenix announces $15M private placement with existing investorsNovember 18, 2022 | finance.yahoo.comSynaptogenix Announces $15 Million Private Placement with Existing InvestorsOctober 22, 2022 | ca.finance.yahoo.comCompanies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In GrowthOctober 19, 2022 | finance.yahoo.comSynaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022September 28, 2022 | finance.yahoo.comSynaptogenix Welcomes Lecanemab Phase 3 Trial ResultsAugust 17, 2022 | marketscreener.comSYNAPTOGENIX, INC. : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K) - Marketscreener.comAugust 12, 2022 | stockhouse.com2022-08-12 | NDAQ:SNPX | Press Release | Synaptogenix Inc. - StockhouseAugust 12, 2022 | finance.yahoo.comSynaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network - Yahoo FinanceAugust 12, 2022 | gurufocus.comSynaptogenix Announces Live Ap - GuruFocus.comAugust 6, 2022 | marketscreener.comSynaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.comJuly 26, 2022 | finance.yahoo.comSynaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data - Yahoo FinanceJuly 26, 2022 | prnewswire.comSynaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data - PR NewswireJuly 26, 2022 | finance.yahoo.comSynaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 DataJuly 20, 2022 | benzinga.comRecap of Wednesday’s Biotech Catalysts - End of The Day Summary - Benzinga - BenzingaJuly 20, 2022 | benzinga.comSynaptogenix Advances Dosing Of First Patient In Dose Optimization Clinical Trial In Preparation For NIH- - BenzingaJuly 20, 2022 | prnewswire.comSynaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data - PR NewswireJuly 20, 2022 | finance.yahoo.comSynaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial DataJuly 13, 2022 | gurufocus.comIROQUOIS CAPITAL NOMINATES SLA - GuruFocus.comJune 30, 2022 | gurufocus.comSynaptogenix to Present at Sac - GuruFocus.comJune 23, 2022 | finance.yahoo.comIROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING - Yahoo FinanceJune 16, 2022 | gurufocus.comSynaptogenix to Present at the Cell Symposium - GuruFocus.comJune 14, 2022 | marketbeat.comTrading was temporarily halted for "SNPX" at 09:06 AM with a stated reason of "LULD pause."May 17, 2022 | prnewswire.comSynaptogenix to Present at the Cell Symposium - PR NewswireMay 17, 2022 | finance.yahoo.comSynaptogenix to Present at the Cell Symposium Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Americans Now Need $1.46M to Retire… (Ad)Americans now say they need $1.46M in order to “retire comfortably.” For many, retiring in your 60s may be out of the picture altogether… But luckily for you – a limited window in today’s crypto market could help you retire quickly in wealth AND comfort! Click here to access the free Crypto Retirement Blueprint now. SNPX Media Mentions By Week SNPX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNPX News Sentiment▼1.470.55▲Average Medical News Sentiment SNPX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNPX Articles This Week▼20▲SNPX Articles Average Week Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Genprex News NexImmune News Seelos Therapeutics News First Wave BioPharma News ZyVersa Therapeutics News Cingulate News Kazia Therapeutics News Protagenic Therapeutics News Petros Pharmaceuticals News Sonnet BioTherapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNPX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsThe 1,000X Crypto PlaybookTrue Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityThe #1 Crypto for AIWeiss RatingsWhy Is Gold On a MASSIVE rally? Huge AlertsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
